Danish biotech Orphazyme raised a €20 million ($24 million) B round to fund its work on rare lysosomal storage disorders, tapping an investor syndicate that includes Novo Nordisk’s venture arm as it rolls toward Phase II trials.

…read more

Source: Orphazyme hauls in $24M to advance its rare disease contender


0 No comments